| 摘要 |
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, more specifically to diagnostic techniques by introducing radiochemicals in a human body. It involves intravenous introduction of a radiopharmaceutical (RP), measurement of RP activity in a full syringe (Q1), in the syringe after injection (Q2) and in an injection point (Q3) by a scintillation camera, scintigram recording, calculation of RP uptake and distribution by formula; and it is labelled short-life radionuclide Technemag 99m Tc taken in the amount 37-185 mBq that is injected intravenously; and dynamic scintigraphy with continuous frame recording for 20 min and exposure of each frame for 20 sec is followed with pulse count for 100-120 sec in the scintigram areas corresponding to the left (Ns) and right (Nd) kidneys, and in the soft tissue areas below the images of proper kidneys (ns) and (nd) and calculation of functioning parenchyma dimensions (FPD), % for each kidney by formulas: and where FPD(s) and FPD(d) are functioning parenchyma dimensions in the left and right kidneys respectively; Q1 - activity in the full syringe before injection; Q2 - activity in the syringe after injection; Q3 - activity in the RP injection point. The FPD values for each kidney within 6.4-8.1%, and total VFP(s) +VFP(d) within 12.8 to 16.2% in patients with two kidneys ensure to diagnose normal functional activity of renal parenchyma, while the FPD values for each kidney less than 6.4 % shows decreased functional activity of renal parenchyma that requires therapeutic correction. ^ EFFECT: method provides higher diagnostic significance in detecting disordered functional activity of renal parenchyma. ^ 3 ex |
